NCT06561009View on ClinicalTrials.gov

Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2028

Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
DRUG

Anti-BAFFR CART

Anti-BAFFR CART

All Listed Sponsors
lead

Tianjin Medical University General Hospital

OTHER

NCT06561009 - Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder | Biotech Hunter | Biotech Hunter